May 6, 2021
Hospira recalls one lot each of 0.5% Bupivacaine and 1% Lidocaine because of mislabeling
Editor's Note
Hospira Inc, a Pfizer company, announced May 4 that it is recalling lot EG6023 of 0.5% Bupivacaine Hydrochloride Injection, USP 30 mL and lot EG8933 of 1% Lidocaine HCL Injection, USP 30 mL because of mislabeling.
A portion of each lot was incorrectly labeled as the other product. The issue was identified by a customer.
Use of the impacted products could cause adverse events of moderate to high severity.
Free Daily News
- CMS plan to phase out inpatient only list sparks debate over safety for vulnerable patients
- ACS issues new best practices for managing genitourinary trauma
- Complex aortic surgery shown safe with minimally invasive approach
- Drug that makes tumors glow is transforming cancer surgery
- Surgical robotics market accelerates as new players challenge industry giants
- Robotic surgery boosts 3-year relapse-free survival in rectal cancer
- Low-cost simulation helps surgical trainees practice crisis skills for major hemorrhage
- Nurse leaders weigh in on NCLEX pass rate decline, impact on workforce readiness
- FDA issues early alerts on multiple high-risk device recalls from J&J, Medtronic, Baxter, Boston Scientific
- New UCSF measure shows 1 in 60 cesarean deliveries involve serious surgical complications
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement